NCT05579340Active, not recruiting
Postoperative Exercise Training and Colorectal Cancer Liver Metastasis
Post-Operative Exercise Training in Patients With Metastatic Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
Up to 25% of colorectal cancer (CRC) patients are diagnosed with liver metastases, which is the most common site of metastasis, already during the primary tumor diagnosis. Another 30% of the patients will develop liver metastases at a later stage. Even though patient can be treated by surgical resection of the metastatic tumor, 50-75% of the patients experience a relapse in less than two years. Due to the high probability of relapse, mCRC patients undergo multiple rounds of surgery and adjuvant treatment (chemotherapy/radiotherapy) which results in substantial physical de-conditioning. Physical activity has been shown to increase the progression-free survival rates in mCRC patients, when applied post-diagnosis. Increased cardiorespiratory fitness (VO2peak) at the time of diagnosis among CRC individuals has been associated with lower risk of all-cause mortality. Although data on the effect of chronic exercise on VO2peak have emerged, thus far, there is no randomized clinical trial that has investigated the effects of exercise training in mCRC patients early after surgical treatment with curative intent. Therefore, this project aims to address the beneficial effect of structured exercise training primarily on VO2peak and tumor recurrence in mCRC patients immediately after surgical treatment and while they are undergoing adjuvant chemotherapy/radiotherapy. A total of 66 participants will be recruited from the Department of Surgery and Transplantation, Rigshospitalet and randomly allocated to a standard care control group (n=22), standard care plus 150 min/week exercise training (n=22) or standard care plus 300 min/week exercise training (n=22). Participants will undergo exercise training for 6 months, starting immediately after surgery, and they will be followed for additional 6 months. Tumor recurrence will be evaluated up to 3 years after training initiation.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 22 Sept 2022
- Start date
- 18 Apr 2023
- Primary completion date
- Jun 2026
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Diseases
- Colorectal cancer
- NCT number
- NCT05579340
What you commit to
- Study type: Interventional
- Planned participants: 66
- From 18 Apr 2023 to the primary completion date, Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \<18
Other
- Pregnancy
- Physical or mental disabilities that prohibit execution of test or training procedures
- Inability to understand the Danish language.
Who the study is looking for
- Colorectal cancer patients diagnosed with liver metastasis and scheduled for liver metastasis surgical resection
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet (CFAS) Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.